Patents by Inventor Keiichi Itakura

Keiichi Itakura has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240011036
    Abstract: Provided herein are, inter alia, KIAA0930 inhibitors, pharmaceutical compositions, and methods for treating and preventing wasting syndromes, such as cancer cachexia.
    Type: Application
    Filed: July 10, 2023
    Publication date: January 11, 2024
    Inventors: Keiichi Itakura, Takahiro Yamakawa
  • Publication number: 20060014178
    Abstract: Mrf-2 is essential for accumulation of lipid stores in postnatal life. Homozygous loss of the ARID gene Mrf-2 resulted in a high rate of neonatal mortality that was partially strain-dependent in mice. Loss of Mrf-2 expression did not affect embryonic survival, embryonic growth or birth weight. Lipid accumulation was severely reduced in brown adipose of Mrf-2?/? neonates at 24 hours of age, however, and Mrf-2?/? mice weighed significantly less than controls from postnatal day five onward. Adult Mrf-2?/? mice were lean, with significant reductions in brown and white adipose tissues, and in the percentage of body fat. Mrf-2?/? and Mrf-2± mice were also resistant to weight gains and obesity when maintained on high fat diets.
    Type: Application
    Filed: May 25, 2005
    Publication date: January 19, 2006
    Inventors: Robert Whitson, Keiichi Itakura
  • Patent number: 5750380
    Abstract: A first polynucleotide is formed with a first particular sequence of nucleotides such as by providing a solid-phase support and adding nucleotides to the support. A second polynucleotide is formed in a similar manner with a second particular sequence of nucleotides which are complementary to the nucleotides in the first polynucleotide at first particular ends of the polynucleotides. The first particular ends may be the 3'-ends of the polynucleotides. The polynucleotides are hybridized or annealed at their 3'-ends to form a base-pair complementary stretch between the first and second polynucleotides. A repair synthesis is then provided in the first and second polynucleotides at second ends (such as the 5'-ends) opposite the first particular ends to provide a double-stranded polynucleotide. The repair synthesis may be monitored by labelling the second end (or 5'-end) of one or both of the nucleotides with radioactivity and then subjecting the nucleotides to an enzymatic reaction.
    Type: Grant
    Filed: April 18, 1995
    Date of Patent: May 12, 1998
    Assignee: City of Hope Research Institute
    Inventors: Keiichi Itakura, John J. Rossi
  • Patent number: 5583013
    Abstract: The Specification discloses:1. Recombinant microbial cloning vehicles comprising heterologous DNA coding for the expression of mammalian hormone (e.g., somatostatin) and other polypeptides, including plasmids suited for the transformation of bacterial hosts. The latter incorporate a regulon homologous to the host in its untransformed state, in reading phase with the structural gene for the heterologous DNA;2. Cloning vehicles coding for the microbial expression of a protein variously comprising (a) a polypeptide hapten and additional protein sufficient in size to confer immunogenicity on the product of expression, which may find use in raising antibodies to the hapten for assay use or in the manufacture of vaccines; and (b) a desired polypeptide product and additional protein from which the desired product may be cleaved; and3. Methods of preparing synthetic structural genes coding for the expression of mammalian polypeptides in microbial cloning systems.
    Type: Grant
    Filed: May 2, 1995
    Date of Patent: December 10, 1996
    Assignee: Genentech, Inc.
    Inventors: Keiichi Itakura, Arthur D. Riggs
  • Patent number: 5221619
    Abstract: The Specification discloses:1. Recombinant microbial cloning vehicles comprising heterologous DNA coding for the expression of mammalian hormone (e.g., somatostatin) and other polypeptides, including plasmids suited for the transformation of bacterial hosts. The latter incorporate a regulon homologous to the host in its untransformed state, in reading phase with the structural gene for the heterologous DNA;2. Cloning vehicles coding for the microbial expression of a protein variously comprising (a) a polypeptide hapten and additional protein sufficient in size to confer immunogenicity on the product of expression, which may find use in raising antibodies to the hapten for assay use or in the manufacture of vaccines; and (b) a desired polypeptide product and additional protein from which the desired product may be cleaved; and3. Methods of preparing synthetic structural genes coding for the expression of mammalian polypeptides in microbial cloning systems.
    Type: Grant
    Filed: January 15, 1992
    Date of Patent: June 22, 1993
    Assignee: Genentech, Inc.
    Inventors: Keiichi Itakura, Arthur D. Riggs
  • Patent number: 4704362
    Abstract: The Specification discloses:1. Recombinant microbial cloning vehicles comprising heterologous DNA coding for the expression of mammalian hormone (e.g., somatostatin) and other polypeptides, including plasmids suited for the transformation of bacterial hosts. The latter incorporate a regulon homologous to the host in its untransformed state, in reading phase with the structural gene for the heterologous DNA;2. Cloning vehicles coding for the microbial expression of a protein variously comprising (a) a polypeptide hapten and additional protein sufficient in size to confer immunogenicity on the product of expression, which may find use in raising antibodies to the hapten for assay use or in the manufacture of vaccines; and (b) a desired polypeptide product and additional protein from which the desired product may be cleaved; and3. Methods of preparing synthetic structural genes coding for the expression of mammalian polypeptides in microbial cloning systems.
    Type: Grant
    Filed: November 5, 1979
    Date of Patent: November 3, 1987
    Assignee: Genentech, Inc.
    Inventors: Keiichi Itakura, Arthur D. Riggs
  • Patent number: 4598049
    Abstract: A microprocessor controlled, general purpose gene synthesizer for programmably synthesizing selected nucleotide sequences. Depending upon a programmed chemistry, metered volumes of selected bases and reagent/solvents are sequentially metered into the bottom of a reaction cell containing solid-supported nucleotides, where desired linkages are achieved in an agitated suspension. Self-refilling syringe metering and electrically initiated, pneumatically operated valving insures economical, non-contaminated synthesis. Preprogrammed, selectable chemistries and operator programmed sequences are operatively coupled under microprocessor control to ensure a general purpose synthesizer.
    Type: Grant
    Filed: August 31, 1983
    Date of Patent: July 1, 1986
    Assignee: Systec Inc.
    Inventors: Richard J. Zelinka, Keiichi Itakura, Carl W. Sims, Bruce E. Kaplan
  • Patent number: 4571421
    Abstract: The specification discloses:1. Recombinant microbial cloning vehicles comprising heterologous DNA coding for the expression of mammalian hormone (e.g., somatostatin) and other polypeptides, including plasmids suited for the transformation of bacterial hosts. The latter incorporate a regulon homologous to the host in its untransformed state, in reading phase with the structural gene for the heterologous DNA;2. Cloning vehicles coding for the microbial expression of a protein variously comprising (a) a polypeptide hapten and additional protein sufficient in size to confer immunogenicity on the product of expression, which may find use in raising antibodies to the hapten for assay use or in the manufacture of vaccines; and (b) a desired polypeptide product and additional protein from which the desired product may be cleaved; and3. Methods of preparing synthetic structural genes coding for the expression of mammalian polypeptides in microbial cloning systems.
    Type: Grant
    Filed: July 30, 1982
    Date of Patent: February 18, 1986
    Assignee: Genentech, Inc.
    Inventor: Keiichi Itakura
  • Patent number: 4401796
    Abstract: A resin support formed from a suitable resin such as polystyrene or a silica gel may be provided by forming an amino resin and by reacting the amino resin with an activated ester of a nucleoside to obtain the dimethoxytrityl resin. To add each successive nucleotide to the resin support, the nucleoside is phosphorylated to provide a monotriazolide. The phosphorylation may be provided by the reaction of a phosphoditriazolide with a 3'-hydroxyl neucleoside. The dimethoxytrityl resin is then hydroxylated to substitute the hydroxyl group for the dimethoxytrityl group in the resin support. The monotriazolide is then reacted with the hydroxylated resin support to provide the dimethoxytrityl resin. This reaction may occur in the presence of a nucleophilic catalyst, such as a catalyst selected from a group consisting of dimethylaminopyridine, N'-methylimidazole and tetrazole.
    Type: Grant
    Filed: April 30, 1981
    Date of Patent: August 30, 1983
    Assignee: City of Hope Research Institute
    Inventor: Keiichi Itakura
  • Patent number: 4373071
    Abstract: A commercially available resin such as polystyrene is converted into a phthalimidomethyl-resin by treatment with potassium phthalimide. The phthalimidomethyl-resin is converted into an amino resin with hydrazine in ethanol. The amino resin is then combined with an activated ester of a nucleoside to obtain an amide-bonded dimethoxytrityl resin. The activated ester of the nucleoside is obtained by reacting a nucleoside with succinic anhydride in the presence of 4-(dimethylamino) pyridine in pyridine to provide a monosuccinate derivative, which is in turn treated with pentachlorophenol and dicyclohexylcarbodimide in dimethylformamide. Any unreacted amino groups in the amide-bonded dimethoxytrityl resin may be masked and the dimethoxytrityl group may be removed by treatment of the amide-bonded resin with a solution of benzenesulfonic acid to obtain a hydroxylated resin support.
    Type: Grant
    Filed: April 30, 1981
    Date of Patent: February 8, 1983
    Assignee: City of Hope Research Institute
    Inventor: Keiichi Itakura
  • Patent number: 4356270
    Abstract: The Specification discloses:1. Recombinant microbial cloning vehicles comprising heterologous DNA coding for the expression of mammalian hormone (e.g., somatostatin) and other polypeptides, including plasmids suited for the transformation of bacterial hosts. The latter incorporate a regulon homologous to the host in its untransformed state, in reading phase with the structural gene for the heterologous DNA;2. Cloning vehicles coding for the microbial expression of a protein variously comprising (a) a polypeptide hapten and additional protein sufficient in size to confer immunogenicity on the product of expression, which may find use in raising antibodies to the hapten for assay use or in the manufacture of vaccines; and (b) a desired polypeptide product and additional protein from which the desired product may be cleaved; and3. Methods of preparing synthetic structural genes coding for the expression of mammalian polypeptides in microbial cloning systems.
    Type: Grant
    Filed: November 5, 1979
    Date of Patent: October 26, 1982
    Assignee: Genentech, Inc.
    Inventor: Keiichi Itakura